John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 9,100 shares at $160.56 ($1.5M) on 2021-08-16, disclosed to the SEC on 2021-08-18.
Open-market sale of $1.5M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $157.31 | 300 | $47K | 3.2% |
| 2 | $158.84 | 1,310 | $208K | 14.3% |
| 3 | $158.84 | 1,310 | $208K | 14.3% |
| 4 | $159.93 | 2,790 | $446K | 30.7% |
| 5 | $159.93 | 2,790 | $446K | 30.7% |
| 6 | $160.56 | 600 |
| $96K |
| 6.6% |
| Total | $159.57 avg | 9,100 | $1.5M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |